Abstract: The present invention relates to a process for purification of iodinated X-ray contrast agents and in particular to purification of crude dimeric contrast agents, such as Iodixanol and Ioforminol. More particularly, the invention relates to purification of such X-ray contrast agents using membrane technology to remove monomeric impurities.

Abstract: The present invention relates to a process for purification of iodinated X-ray contrast agents and in particular to purification of crude dimeric contrast agents, such as Iodixanol and Ioforminol. More particularly, the invention relates to purification of such X-ray contrast agents using membrane technology to remove monomeric impurities.

Abstract: The invention relates to a composition comprising a non-ionic X-ray contrast agent in a pharmaceutically acceptable carrier, and particularly to a supersaturated X-ray composition comprising X-ray contrast agents with a high dissolution temperature in water. Particularly, the invention provides such composition which is stable, and wherein crystallisation during storage is avoided. In a preferred aspect the X-ray contrast agent is Ioforminol and the composition includes a nucleation- and growth inhibitor. The invention further relates to a process for the preparation of such stable diagnostic X-ray composition.

Abstract: The invention describes a process for the purification of iodinated aryl compounds where the purification is performed by continuous crystallization of a crude product in a solvent with addition of anti-solvent. The continuous crystallization process is performed in one or more crystallizers at a temperature up to the boiling point of the content of the crystallizer.

Abstract: A process for the manufacture of iodixanol by performing a purification process of the crude product in a solvent comprising 1-methoxy-2-propanol. The crude product may be obtained in aqueous solution from dimerization of 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-isophthalamide (“Compound A”).

Abstract: The invention describes a process for the purification of iodinated aryl compounds where the purification is performed by continuous crystallization of a crude product in a solvent with removal of at least a fraction of the solvent. The continuous crystallization process is performed in one or more crystallizers at the boiling point of the content of the crystallizer.

Abstract: This invention relates to an improved method for the synthesis of 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (“Compound A”), an intermediate in the industrial preparation of non-ionic X-ray contrast agents. In particular, it relates to a continuous process of acetylation of 5-amino-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide (“Compound B”) followed by the removal of acetic anhydride.

Abstract: This invention relates to an improved method for the synthesis of 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide (“Compound A”), an intermediate in the industrial preparation of non-ionic X-ray contrast agents. In particular, it relates to a continuous process of deacetylation of the acetylated hydroxyl group in 5-amino-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide (“Compound B”) followed by crystallisations, filtration, and washing of Compound A.

Abstract: A process for the manufacture of iodixanol by performing a purification process of the crude product in a solvent comprising 1-methoxy-2-propanol. The crude product may be obtained in aqueous solution from dimerisation of 5-acetamido-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-isophthalamide (“Compound A”).

Abstract: The invention describes a process for the purification of iodinated aryl compounds where the purification is performed by continuous crystallisation of a crude product in a solvent with addition of anti-solvent. The continuous crystallisation process is performed in one or more crystallisers at a temperature up to the boiling point of the content of the crystalliser.

Abstract: The invention describes a process for the purification of iodinated aryl compounds where the purification is performed by continuous crystallisation of a crude product in a solvent with removal of at least a fraction of the solvent. The continuous crystallisation process is performed in one or more crystallisers at the boiling point of the content of the crystalliser.

Abstract: The present invention relates to a process for the manufacture of iohexol, 5-[N-(2,3-dihydroxypropyl)-acetamido]-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophtalamide by selecting a solvent comprising a C1-C5-monoalkylether of a C3-C10 alkylene-glycol.

Abstract: A process for the crystallisation of a sterically hindered organic compound from a saturated or supersaturated solution of said compound in a solvent therefor, characterised in that crystallisation is effected under elevated pressure at a temperature above the boiling point of said solution at atmospheric pressure and up to the boiling point of said solution at said elevated pressure.

Abstract: A process for the crystallisation of a sterically hindered organic compound from a saturated or supersaturated solution of said compound in a solvent therefor, characterised in that crystallisation is effected under elevated pressure at a temperature above the boiling point of said solution at atmospheric pressure and up to the boiling point of said solution at said elevated pressure.